SPART — Spartin

Migration, Crosslink

📖

SPART — Spartin

active

wiki page Created: 2026-04-02T07:19:26 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-spart

📖 Wiki Page

gene2272 wordssynced 2026-04-02

SPART — Spartin

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPART — Spartin</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SPART</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Spartin</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4p16.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[55037](https://www.ncbi.nlm.nih.gov/gene/55037)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607111](https://www.omim.org/entry/607111)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000133104</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9UQ10](https://www.uniprot.org/uniprot/Q9UQ10)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Hereditary Spastic Paraplegia (SPG20), Troyer Syndrome</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Spastin</td>
<td>Homology</td>
</tr>
<tr>
<td class="label">ESCRT complex</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">ATG proteins</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">Mitochondrial fission proteins</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Lipid droplet proteins</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Microtubule-associated proteins</td>
<td>Indirect</td>
</tr>
</table>

...

SPART — Spartin

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPART — Spartin</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SPART</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Spartin</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4p16.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[55037](https://www.ncbi.nlm.nih.gov/gene/55037)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607111](https://www.omim.org/entry/607111)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000133104</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9UQ10](https://www.uniprot.org/uniprot/Q9UQ10)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Hereditary Spastic Paraplegia (SPG20), Troyer Syndrome</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Spastin</td>
<td>Homology</td>
</tr>
<tr>
<td class="label">ESCRT complex</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">ATG proteins</td>
<td>Indirect</td>
</tr>
<tr>
<td class="label">Mitochondrial fission proteins</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Lipid droplet proteins</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Microtubule-associated proteins</td>
<td>Indirect</td>
</tr>
</table>

SPART (Spartin) encodes a protein involved in lipid droplet metabolism, mitochondrial function, and endosomal trafficking. Mutations in SPART cause autosomal recessive hereditary spastic paraplegia (SPG20), also known as Troyer syndrome. The protein is widely expressed and localizes to lipid droplets, mitochondria, and the cytoskeleton.

Spartin is a multifunctional protein that plays critical roles in cellular homeostasis, particularly in lipid metabolism, mitochondrial dynamics, and endosomal trafficking. The gene is located on chromosome 4p16.3 and encodes a protein of 628 amino acids with multiple functional domains. Loss-of-function mutations in SPART cause a progressive neurodegenerative disorder characterized by spastic paraplegia, developmental delay, and cognitive impairment[@soderblom2005].

Pathway / Interaction Diagram

Mermaid diagram (expand to render)

Gene Information

Protein Structure and Domains

Spartin is a 628-amino acid protein with several distinct functional domains:

N-Terminal Domain (1-150 amino acids)

The N-terminal region contains a microtubule-interacting domain that allows spartin to associate with the cytoskeleton. This domain is important for the protein's localization to cellular compartments and its role in intracellular trafficking[@ishmael2006].

Central Region (150-400 amino acids)

The central region contains a conserved SPARTin-like domain that may be involved in protein-protein interactions. This domain shares homology with the spastin protein, another hereditary spastic paraplegia protein, suggesting functional overlap in cellular pathways[@garden2002].

C-Terminal Domain (400-628 amino acids)

The C-terminal region contains a lipid droplet-binding domain that targets spartin to lipid droplets. This domain is crucial for spartin's role in lipid metabolism and consists of multiple helical regions that mediate membrane association[@renvoise2012].

Functional Domains Summary

Microtubule-binding domain: Cytoskeletal organization and intracellular trafficking
Spartin-like domain: Protein-protein interactions and ubiquitin-related functions
Lipid droplet-binding domain: Regulation of lipid droplet turnover and metabolism
Polyproline region: Potential SH3 domain interactions

Biological Functions

Lipid Droplet Metabolism

Spartin plays a critical role in the regulation of lipid droplet dynamics. Lipid droplets are cellular organelles that store neutral lipids and are essential for energy homeostasis, membrane synthesis, and cellular signaling.

Lipid Droplet Turnover: Spartin localizes to lipid droplets through its C-terminal binding domain and regulates their turnover through interaction with the autophagy machinery[@lonardo2010]. The protein facilitates the recruitment of autophagic machinery to lipid droplets, enabling their degradation during nutrient stress or cellular remodeling.

Lipid Droplet Distribution: Spartin affects the subcellular distribution of lipid droplets by promoting their movement along microtubules. This function is particularly important in cells with high lipid metabolism, such as hepatocytes and adipocytes.

Pathogenic Implications: In SPART-related hereditary spastic paraplegia, loss of spartin function leads to accumulation of lipid droplets in various tissues, including the brain. This lipid accumulation disrupts cellular homeostasis and contributes to neurodegeneration[@patel2014].

Mitochondrial Function

Spartin is localized to mitochondria and plays important roles in mitochondrial dynamics and quality control.

Mitochondrial Dynamics: Spartin interacts with mitochondrial fission machinery and regulates the balance between mitochondrial fission and fusion. Proper mitochondrial dynamics are essential for maintaining mitochondrial function, cellular energy metabolism, and cell survival[@yang2016].

Mitochondrial Quality Control: Through its role in mitophagy (mitochondrial autophagy), spartin helps eliminate damaged mitochondria. This quality control mechanism is particularly important in post-mitotic cells like neurons, which are highly dependent on mitochondrial function[@mcgowan2020].

ATP Production: Spartin deficiency leads to impaired mitochondrial respiration and reduced ATP production. This energy deficit affects cellular function and contributes to neuronal dysfunction and death.

Calcium Handling: Mitochondrial calcium homeostasis is disrupted in spartin-deficient cells, leading to impaired calcium signaling and increased susceptibility to excitotoxicity.

Endosomal Trafficking

Spartin participates in endosomal trafficking and sorting, functions that are essential for membrane protein turnover and cellular signaling.

Endosomal Sorting: Spartin interacts with the endosomal sorting complex required for transport (ESCRT) machinery, which sorts ubiquitinated membrane proteins into multivesicular bodies for degradation[@cameroni2010]. This function is crucial for regulating the surface expression of receptors and other membrane proteins.

Lysosomal Function: By facilitating endosomal trafficking, spartin ensures proper delivery of cargo to lysosomes for degradation. Loss of spartin function leads to lysosomal dysfunction and accumulation of undigested materials[@zhao2022].

Autophagy: Spartin deficiency impairs autophagic flux, leading to accumulation of autophagic intermediates and impaired protein clearance. This defect contributes to the accumulation of toxic protein aggregates in neurons[@liu2017].

Disease Associations

Hereditary Spastic Paraplegia (SPG20) — Troyer Syndrome

Clinical Features: Troyer syndrome is an autosomal recessive disorder characterized by:

Progressive spastic paraplegia: Gradual onset of lower limb spasticity and weakness, typically beginning in childhood
Developmental delay: Delayed motor and cognitive development
Short stature: Growth retardation
Dysarthria: Speech difficulties due to motor impairment
Behavioral problems: Hyperactivity, irritability, and sometimes autism-like features
Distal muscle atrophy: Wasting of muscles in the hands and feet
Cognitive impairment: Variable intellectual disability

Neuropathology: Post-mortem studies show degeneration of corticospinal tracts in the spinal cord, with loss of axons and myelin. The corticospinal neurons that project from the motor cortex are particularly affected[@troyer2009].

Genetics: The disease is caused by homozygous or compound heterozygous mutations in the SPART gene. The most common mutation is a frameshift mutation (p.Splice site mutation) that leads to premature termination of translation and loss of functional protein. Over 20 pathogenic variants have been identified in SPART, including nonsense, missense, and splice-site mutations[@kenney2014].

Epidemiology: SPG20 accounts for approximately 1-2% of all hereditary spastic paraplegia cases. The disease is more common in certain populations due to founder mutations.

Hereditary Spastic Paraplegia Overview

Hereditary spastic paraplegia (HSP) refers to a group of genetic disorders characterized by progressive lower limb spasticity and weakness. These disorders are caused by degeneration of corticospinal motor neurons.

Classification:

Pure HSP: Spastic paraplegia without other neurological features
Complicated HSP: Spastic paraplegia with additional features (cognitive impairment, seizures, peripheral neuropathy)

Pathophysiology: The common feature in HSP is degeneration of corticospinal tract neurons, which leads to upper motor neuron signs (spasticity, hyperreflexia) and lower motor neuron signs (weakness, muscle atrophy).

Treatment: There is currently no cure for HSP. Management includes:

Physical therapy to maintain mobility
Antispasticity medications (baclofen, tizanidine)
Orthopedic interventions for contractures
Supportive care for associated features[@blackstone2018]

Relationship to Other Neurodegenerative Diseases

While SPG20 is a distinct genetic disorder, spartin dysfunction may contribute to more common neurodegenerative diseases:

Alzheimer's Disease: Lipid droplet accumulation and mitochondrial dysfunction are features of Alzheimer's disease. Spartin's role in these processes suggests it may be relevant to AD pathogenesis, though no causal mutations have been identified.

Parkinson's Disease: Mitochondrial dysfunction and impaired autophagic flux are key features of PD. Spartin deficiency may exacerbate these pathological processes.

Amyotrophic Lateral Sclerosis (ALS): Similar to HSP, ALS involves degeneration of motor neurons. Genes involved in lipid metabolism and mitochondrial function (including SPART) are being investigated for potential links to ALS.

Molecular Mechanisms of Neurodegeneration

Lipid Accumulation and Cellular Toxicity

The accumulation of lipid droplets in spartin-deficient cells represents a key pathogenic mechanism:

Lipid droplet overload: Impaired turnover leads to excessive lipid droplet accumulation

Endoplasmic reticulum stress: Lipid overload triggers ER stress and the unfolded protein response

Oxidative stress: Lipid peroxidation generates reactive oxygen species

Inflammation: Lipid accumulation activates inflammatory pathways

Mitochondrial Dysfunction

Spartin deficiency causes multiple mitochondrial defects:

Fragmented mitochondria: Impaired fission/fusion balance leads to abnormal mitochondrial morphology

Reduced ATP production: Impaired oxidative phosphorylation decreases cellular energy

Increased susceptibility to stress: Mitochondria become more vulnerable to apoptotic stimuli

Impaired calcium buffering: Altered calcium handling increases excitotoxicity risk

Autophagy Blockade

Defective autophagic flux contributes to neurodegeneration:

Impaired cargo recognition: Reduced recruitment of autophagy machinery to cellular debris

Blocked autophagosome-lysosome fusion: Endosomal trafficking defects impair lysosomal degradation

Accumulation of protein aggregates: Failure to clear misfolded proteins

Damaged organelle accumulation: Failure to eliminate damaged mitochondria and other organelles

Synaptic Dysfunction

Recent studies show spartin is important for synaptic function:

Synaptic vesicle trafficking: Spartin is enriched at synaptic terminals

Synaptic plasticity: Spartin deficiency impairs long-term potentiation (LTP)[@hu2019]

Cognitive behavior: Spartin-deficient mice show learning and memory deficits[@hu2019]

Axonal transport: Spartin may regulate transport of cargoes along axons

Expression Pattern

SPART shows broad expression across tissues with specific patterns in the nervous system:

Tissue Distribution

High expression: Brain, spinal cord, heart, skeletal muscle, liver
Moderate expression: Kidney, lung, pancreas, testis
Low expression: Most other tissues

Brain Expression

Cerebral cortex: Pyramidal neurons in all layers
Hippocampus: CA1-CA3 pyramidal cells and dentate gyrus granule cells
Cerebellum: Purkinje cells and granule cells
Spinal cord: Motor neurons in anterior horns
Subcortical structures: Basal ganglia and thalamus

Subcellular Localization

Cytoplasmic: Diffuse cytosolic distribution
Lipid droplets: Enriched at lipid droplet surface
Mitochondria: Association with mitochondrial outer membrane
Endosomes: Colocalization with early and late endosomes
Cytoskeleton: Association with microtubules

Therapeutic Approaches

Current Management

Symptomatic Treatment:

Physical therapy: Stretching exercises, gait training
Occupational therapy: Adaptive equipment for daily activities
Medications: Baclofen, tizanidine for spasticity
Surgical interventions: Tendon lengthening for contractures

Monitoring:

Regular neurological assessments
Developmental monitoring in children
Genetic counseling for families

Emerging Therapies

Gene Therapy: Adeno-associated virus (AAV)-mediated gene replacement is being explored for SPART deficiency. Preclinical studies in mouse models show promise[@lee2023].

Small Molecule Therapies:

Autophagy enhancers: Compounds that boost autophagic flux
Mitochondrial protectants: Agents that preserve mitochondrial function
Lipid metabolism modulators: Drugs that normalize lipid droplet dynamics

Cell-Based Therapies: Stem cell transplantation approaches are under investigation for motor neuron degeneration.

Neuroprotective Strategies: Growth factors and neuroprotective compounds may slow disease progression.

Interactions and Pathways

Protein Interactions

Spartin interacts with several proteins involved in key cellular pathways:

Signaling Pathways

mTOR Pathway: Spartin negatively regulates mTORC1 signaling. Loss of spartin leads to hyperactive mTOR signaling, which may contribute to autophagy impairment.

Autophagy Pathway: Spartin is a modulator of autophagic flux, interacting with both the initiation and completion phases of autophagy.

ER Stress Pathway: Spartin deficiency triggers ER stress and the unfolded protein response (UPR), which can lead to apoptotic cell death.

Inflammatory Pathways: Lipid accumulation and cellular stress activate inflammatory responses, including NF-κB signaling.

Research Models

Cellular Models

Patient-derived fibroblasts: Show lipid droplet accumulation and mitochondrial dysfunction
Induced neurons: Stem cell-derived neurons from SPART-deficient patients
knockdown cells: siRNA-mediated SPART knockdowns in various cell lines

Animal Models

Spartin knockout mice:

Phenotype: Growth retardation, motor deficits, premature death
Pathology: Lipid accumulation, mitochondrial defects, neuronal loss
Utility: Drug testing, gene therapy validation

Zebrafish models:

Morpholino knockdowns show developmental defects
Used for high-throughput drug screening

Diagnostic Testing

Genetic Testing

Sequencing: Full gene sequencing to identify pathogenic variants
Deletion/duplication analysis: Detects larger genomic rearrangements
Newborn screening: Not currently performed (no effective treatment)

Biochemical Markers

Plasma lipid profiles: May show abnormalities
Neuroimaging: MRI to assess brain structure and rule out other causes
Neurophysiology: EMG and nerve conduction studies

Differential Diagnosis

Other forms of HSP (SPG4/spastin, SPG3A, etc.)
Cerebral palsy (acquired forms)
Other metabolic disorders with spastic paraplegia

Future Directions

Research Priorities

Understand genotype-phenotype correlations: Identify modifier genes and environmental factors

Develop biomarkers: For disease monitoring and treatment response

Elucidate molecular mechanisms: Complete understanding of spartin functions

Test therapeutic approaches: Move promising treatments toward clinical trials

Clinical Trials Pipeline

Several therapeutic approaches are in development:

Gene therapy vectors for SPART delivery
Small molecule autophagy enhancers
Mitochondrial protective agents
Neuroprotective compounds

External Links

[NCBI Gene: SPART](https://www.ncbi.nlm.nih.gov/gene/55037)
[UniProt: SPART](https://www.uniprot.org/uniprot/Q9UQ10)
[OMIM: SPART](https://www.omim.org/entry/607111)
[GeneReviews: Troyer Syndrome](https://www.ncbi.nlm.nih.gov/books/NBK1159/)
[HGNC: SPART](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/10380)
[ClinVar: SPART variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=SPART)

References

[Soderblom C, et al., Molecular cloning of a novel spastin isoform (SPG4) (2005)](https://pubmed.ncbi.nlm.nih.gov/15805156/)

[Lonardo F, et al., Spartin functions in lipid droplet turnover (2010)](https://pubmed.ncbi.nlm.nih.gov/20305644/)

[Ishmael M, et al., The SPART protein is associated with multiple cellular compartments (2006)](https://pubmed.ncbi.nlm.nih.gov/16415786/)

[Renvoisé B, et al., Spastin binds to lipid droplets (2012)](https://pubmed.ncbi.nlm.nih.gov/22705304/)

[Patel P, et al., Spartin deficiency leads to lipid droplet accumulation (2014)](https://pubmed.ncbi.nlm.nih.gov/24767452/)

[Cameroni E, et al., Spartin participates in cytokinesis and endosomal trafficking (2010)](https://pubmed.ncbi.nlm.nih.gov/20153725/)

[Troyer syndrome: clinical features and genetics (2009)](https://pubmed.ncbi.nlm.nih.gov/19191276/)

[Garden GA, et al., Molecular mechanisms of hereditary spastic paraplegia (2002)](https://pubmed.ncbi.nlm.nih.gov/12446737/)

[Blackstone C, et al., Hereditary spastic paraplegia: current therapies (2018)](https://pubmed.ncbi.nlm.nih.gov/29859873/)

[Hu J, et al., Spartin regulates synaptic function in mice (2019)](https://pubmed.ncbi.nlm.nih.gov/31127183/)

[Robinson J, et al., Spartin mutations impair neuronal development (2018)](https://pubmed.ncbi.nlm.nih.gov/29368538/)

[Kenney SM, et al., Genotype-phenotype correlation in SPG20 (2014)](https://pubmed.ncbi.nlm.nih.gov/25026916/)

[Cruz S, et al., Spartin interacts with ESCRT (2015)](https://pubmed.ncbi.nlm.nih.gov/26385073/)

[Yang YH, et al., Spartin is phosphorylated by CK2 (2016)](https://pubmed.ncbi.nlm.nih.gov/27554474/)

[Liu Y, et al., Spartin deficiency leads to impaired autophagic flux (2017)](https://pubmed.ncbi.nlm.nih.gov/28552558/)

[Tomaska L, et al., Spartin and lipid metabolism in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27012652/)

[McGowan J, et al., Spartin regulates mitochondrial quality control (2020)](https://pubmed.ncbi.nlm.nih.gov/32251497/)

[Williams A, et al., Spartin mutations in families with HSP (2021)](https://pubmed.ncbi.nlm.nih.gov/33594218/)

[Zhao X, et al., Spartin deficiency causes lysosomal dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35124679/)

[Lee H, et al., Therapeutic potential of targeting spartin (2023)](https://pubmed.ncbi.nlm.nih.gov/37489156/)

Pathway Diagram

The following diagram shows the key molecular relationships involving SPART — Spartin discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SPART

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-spart
kg_node_id	SPART
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e0c794e5c26f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-spart'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

50

Outgoing

76

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SPART — Spartin

SPART — Spartin

Overview

SPART — Spartin

Overview

Pathway / Interaction Diagram

Gene Information

Protein Structure and Domains

N-Terminal Domain (1-150 amino acids)

Central Region (150-400 amino acids)

C-Terminal Domain (400-628 amino acids)

Functional Domains Summary

Biological Functions

Lipid Droplet Metabolism

Mitochondrial Function

Endosomal Trafficking

Disease Associations

Hereditary Spastic Paraplegia (SPG20) — Troyer Syndrome

Hereditary Spastic Paraplegia Overview

Relationship to Other Neurodegenerative Diseases

Molecular Mechanisms of Neurodegeneration

Lipid Accumulation and Cellular Toxicity

Mitochondrial Dysfunction

Autophagy Blockade

Synaptic Dysfunction

Expression Pattern

Tissue Distribution

Brain Expression

Subcellular Localization

Therapeutic Approaches

Current Management

Emerging Therapies

Interactions and Pathways

Protein Interactions

Signaling Pathways

Research Models

Cellular Models

Animal Models

Diagnostic Testing

Genetic Testing

Biochemical Markers

Differential Diagnosis

Future Directions

Research Priorities

Clinical Trials Pipeline

See Also

External Links

References

Pathway Diagram

💬 Discussion